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Background: Primary focal dystonia and Parkinson’s disease are movement disorders that 
have contrasting motor phenotypes. The aim of this study was to compare the frequency and 
the severity of psychiatric disorders in primary focal dystonia and Parkinson’s disease.
Methods: Two groups of 30 patients matched by gender and age underwent a neurological 
and psychiatric assessment.
Results: Parkinson’s disease patients were diagnosed with higher rates of major depression 
(P = 0.02) and generalized anxiety disorder (P = 0.02), and greater severity of depressive 
symptoms (P = 0.04), while patients with primary focal dystonia exhibited increased severity 
of obsessive-compulsive symptoms (P = 0.02).
Discussion: The difference in pathophysiology of primary focal dystonia and Parkinson’s disease 
may explain the different psychiatric profiles of these two diseases. The increased frequency of 
affective symptoms in Parkinson’s disease may be related to the fact that Parkinson’s disease 
is a neurodegenerative disease marked by the loss of monoaminergic neurons which does not 
happen in primary focal dystonia.
Conclusion: The psychiatric profile differs in movement disorders with distinct neurobiological 
bases.
Keywords: focal dystonia, Parkinson’s disease, neuropsychiatry, depression, obsessive-
compulsive disorder
Introduction
The study of psychiatric comorbidities in movement disorders has provided meaningful 
insights into the pathophysiology of these conditions. For instance, the observation 
of an outbreak of obsessive compulsive disorder following epidemic encephalitis 
(Encephalitis lethargica) anticipated the role of the basal ganglia in human behavior.1 
The relationship between Sydenham’s chorea and obsessive compulsive disorder also 
reinforces such an idea.2 However, conflicting results and methodological issues prevent 
us from establishing adequate explanatory models for neuropsychiatric disorders.
To investigate whether distinctive psychiatric phenotypes are associated with 
dysfunction of specific corticosubcortical circuits, we propose the comparison of 
the frequency and severity of psychiatric disorders in two movement diseases with 
different pathophysiological features. Dystonia is a neurological hyperkinetic syndrome 
characterized by sustained muscular contractions that cause repetitive movements and 
abnormal postures.3,4 These motor disturbances may affect different body segments 
or involve a single body region, such as the hand, the neck, or the eyes. Dystonia is 
classified according to its etiology into primary, if no cause is identifiable, or secondary, 
when caused by trauma, drugs, and other defined mechanisms.3,4 There is a growing Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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body of evidence linking genetic mutations and primary focal 
dystonia,3,4 which seems to originate from a dysfunction in 
the corticostriatal circuitry.
Conversely, parkinsonism is a hypokinetic syndrome 
characterized by bradykinesia, rigidity, rest tremor, and 
postural instability. Parkinson’s disease is the main cause 
of parkinsonism. The disease is pathologically defined by 
neuronal loss, predominantly in the substantia nigra pars 
compacta, and the presence of Lewy bodies in the remaining 
neurons.5 However, it is currently known that neuronal loss 
extends far beyond the substantia nigra, and may include 
degeneration of regions such as the dorsal IX and X motor 
nucleus, the raphe nuclei, locus coeruleus, and porencephalic 
regions.6 In addition, Parkinson’s disease is probably the 
result of several components acting together, including 
aging, genetic susceptibility, inflammatory processes, and 
environmental factors.7 Treatment with dopaminergic drugs 
improves clinical symptoms without modifying the course 
of the disease. Although the diagnosis of Parkinson’s disease 
is based on motor signs, the nonmotor aspects of the disease 
are extremely common and disabling.7,8
The investigation of psychiatric disorders in focal dystonia 
and Parkinson’s disease needs more consistent data. Studies 
that have systematically assessed psychiatric disorders in 
focal dystonia are scarce in the literature.9–11 Nevertheless, 
psychiatric comorbidities are frequently reported in these 
patients, and probably have a significant impact on clinical 
control and quality of life.10,11 Although there is controversy in 
the literature concerning the prevalence of psychiatric disorders 
in focal dystonia, it is well recognized that depression, anxiety, 
and sleep disturbances are more prevalent in Parkinson’s 
disease patients than in the general population.7
The main objective of this study was to compare the 
frequency and the severity of psychiatric disorders in focal 
dystonia and Parkinson’s disease. Our main hypothesis was 
that these two movement disorders differ in their profile of 
psychiatric symptoms and disorders. If both disorders contrast 
in terms of psychiatric profile, the distinct pathophysiology 
of focal dystonia and Parkinson’s disease might explain this 
difference. The results of this research will contribute to the 
study of nonmotor symptoms of Parkinson’s disease and, 
particularly, focal dystonia. This study might also improve 
our understanding of the role of certain brain structures, such 
as corticostriatal circuitry, in psychiatric disorders.
Methods
study design
This was a cross-sectional study of patients diagnosed with 
focal dystonia or Parkinson’s disease, and who were attending 
the Movement Disorders Clinic of the University Hospital, 
School of Medicine, Federal University of Minas Gerais.
Participants were invited to participate in this study in 
a consecutive manner. Considering that focal dystonia is 
a rare disease, focal dystonia patients were enrolled first. 
Afterwards, Parkinson’s disease patients were consecutively 
recruited in order to match focal dystonia patients according 
to age and gender. None of them refused to participate.
Written informed consent was obtained from all the 
patients. Appropriate comprehension of the consent form by 
the participant and/or his/her companion was assured by the 
researchers. The study was approved by the ethics commit-
tee from the Federal University of Minas Gerais, which also 
approved the consent form. This research was conducted in 
accordance with the Declaration of Helsinki.
inclusion and exclusion criteria
Patients diagnosed with focal dystonia or Parkinson’s 
disease who signed the informed consent were included. 
Both diseases were diagnosed independently by two of the 
authors (FC and ALT) according to the current diagnostic 
criteria.12,13 Dementia, delirium, history of neurosurgery, 
and the presence of any other relevant neurological disease 
were taken as exclusion criteria. Dementia was diagnosed 
according to DSM-IV (Diagnostic and Statistical Manual of 
Mental Disorders, 4th Edition) criteria and according to the 
performance in the Mini Mental State Examination adapted 
for the Brazilian population.14 Delirium was diagnosed 
according to DSM-IV criteria.
recruitment and assessment
Sixty patients (30 with Parkinson’s disease and 30 with 
focal dystonia) were enrolled. Participants were invited to 
participate in the study just before their appointment at the 
University Hospital. All patients underwent a comprehensive 
neurologic examination conducted by ALT. Neurologic 
examination of Parkinson’s disease patients included the 
Unified Parkinson’s Disease Rating Scale (UPDRS), the 
Hoehn–Yahr Scale (HY), and the Schwab–England Scale 
of activities of daily living (SES). UPDRS is an instrument 
which assesses severity of nonmotor symptoms, motor signs, 
and impact on activities of daily living. The HY objectively 
evaluates stages of Parkinson’s disease, and the SES is 
used to assess impact of Parkinson’s disease on daily living 
activities.
The focal dystonia patients had primary focal dystonia. 
Primary dystonia, classically called idiopathic dystonia, 
refers to syndromes in which dystonia is the primary clinical 
manifestation and in which secondary causes have been Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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carefully excluded. Ten patients presented with the cervical 
dystonia subtype, and 20 presented with the blepharospasm 
subtype.
All patients also underwent a psychiatric evaluation 
which included the MINI-Plus,15 an internationally validated 
structured clinical interview for psychiatric diagnosis 
according to DSM-IV , and psychometric scales, including 
the Yale-Brown Obsessive Compulsive Scale (YBOCS),16 the 
Beck Depression Inventory (BDI),17 the Hamilton Anxiety 
Rating Scale (HAM-A),18 and the Liebowitz Social Anxiety 
Scale (LS).19 These instruments were administered by the 
first two authors.
statistical analyses
Comparisons between categorical variables among groups 
were performed using the Fisher’s Exact test. The Mann–
Whitney U test was used for continuous variables. All 
P values were two-tailed, and a significance level of 0.05 was 
chosen. Statistical analysis was performed using the SPSS 
version 17.0 software.
Results
The Parkinson’s disease and focal dystonia groups had the 
same distribution of gender (males 10, females 20) and 
age (mean ± standard deviation [SD] 59.3 ± 11.1). Patients 
did not differ in other demographic features (Table 1). 
Almost half the sample had other medical conditions. 
Severity of Parkinson’s disease according to the UPDRS 
was moderate in most patients (54.0 ± 27.5). HY ranged 
from 1 to 4, with a median of 2. Percentile ratings on the 
SES suggested relatively independent functioning of the 
patients (78 ± 12.7). Most Parkinson’s disease patients were 
using levodopa at a mean dose of 562.9 ± 253.6 mg/day 
(Table 2).
All patients with focal dystonia had been treated with 
botulinum toxin at least once before inclusion in the study. 
All patients but one were still using botulinum toxin. The 
patient who was no longer using botulinum toxin had had 
its use interrupted two years earlier. Focal dystonia patients 
currently using botulinum toxin had been doing so for 
4.8 ± 2.7 years. None of the focal dystonia patients were 
using antidepressants or benzodiazepines. Psychoactive 
medications used by focal dystonia and Parkinson’s disease 
patients are shown in Table 2.
According to the MINI-Plus, patients with Parkinson’s 
disease showed a higher frequency of current major depressive 
disorder (P = 0.02) and generalized anxiety disorder 
(P = 0.02) than focal dystonia patients (Table 3). The severity 
of depressive symptoms was also higher in patients with PD 
in comparison with focal dystonia (P = 0.04), according to 
the BDI (Table 4). The frequency of social phobia, as well 
as the severity of social anxiety, was remarkably high in both 
groups (Tables 3 and 4). The difference in the frequency of 
obsessive compulsive disorder between the groups did not 
reach statistical significance. However, patients with focal 
dystonia scored higher on the YBOCS (P = 0.02).
Discussion
In this research, the results suggest that patients with movement 
disorders may show different patterns of psychiatric disorders 
and symptoms. Patients with Parkinson’s disease are more 
prone to suffer from major depression and generalized 
anxiety disorder. By contrast, it is possible that obsessive-
compulsive symptoms are more frequent in patients with 
focal dystonia.
Our finding of a higher frequency of major depressive 
disorder in Parkinson’s disease differs from the study by 
Table  1  Demographic  and  clinical  features  of  patients  with 
primary focal dystonia and Parkinson’s disease
Primary focal  
dystonia  
(n = 30)
Parkinson’s 
disease  
(n = 30)
P value
gender (M/F) 10/20 10/20 1.00
Age, years,  
(mean ± sD)
59.3 ± 11.1 59.3 ± 11.1 1.00
educational level,  
years, (mean ± sD)
7.8 ± 6.72 5.63 ± 3.91 0.23
Marital status,  
married (%)
16 (53.3) 20 (66.7) 0.29
Age of disease onset, 
years, (mean ± sD)
49.2 ± 12.0 50.6 ± 11.2 0.69
Duration of symptoms, 
years, (mean ± sD)
8.7 ± 4.16 10.0 ± 3.73 0.11
Other medical 
conditions, (%)
16 (53.3) 15 (50.0) 0.79
Abbreviations: sD, standard deviation; M, male; F, female.
Table 2 Psychotropic medications of patients with Parkinson’s 
disease and focal dystonia (n = 30)
Psychoactive medications in PD Frequency (%)*
L-Dopa 25 (83.3%)
Dopaminergic agonist 12 (40.0%)
Anticholinergic drugs 12 (40.0%)
Amantadine 11 (36.7%)
cOMT inhibitors 3 (10.0%)
Antidepressants 14 (46.7%)
Benzodiazepines 5 (16.7%)
Psychoactive medications in FD Score (mean ± SD)
carbamazepine 1 (3.3%)
Anticholinergic 2 (6.6%)
Note: *Proportions exceed 100% because most patients with PD are in polypharmacy. 
Abbreviations:  cOMT,  catechol-O-methyltransferase;  FD,  focal  dystonia;  PD, 
Parkinson’s disease; sD, standard deviation.Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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Table 3 Frequency of current psychiatric diagnosis in patients 
with primary focal dystonia and Parkinson’s disease
Primary focal 
dystonia  
(n = 30)
Parkinson’s 
disease  
(n = 30)
P value
Major depressive  
disorder (%)
5 (16.7) 13 (43.3) 0.02
Dysthymia (%) 2 (6.7) 4 (13.3) 0.39
generalized anxiety 
disorder (%)
4 (13.3) 12 (40) 0.02
Panic disorder (%) 0 (0.0) 2 (6.7) 0.15
social phobia (%) 15 (50) 13 (43.3) 0.60
Specific phobia (%) 3 (10) 5 (16.7) 0.65
hypochondria (%) 3 (10) 0 (0.0) 1.00
Body dysmorphic 
disorder (%)
2 (6.7) 0 (0.0) 1.00
Obsessive compulsive 
disorder (%)
4 (13.3) 1 (3.3) 0.16
Psychotic disorders (%) 1 (3.3) 4 (13.3) 0.16
Tobacco dependence (%) 6 (20) 2 (6.6) 0.13
Alcohol abuse (%) 3 (10.0) 0 (0) 0.08
Table  4  scores  of  patients  with  primary  focal  dystonia  and 
Parkinson’s disease in psychopathological scales
Primary focal 
dystonia  
(n = 30)
Parkinson’s 
disease  
(n = 30)
P value
Beck Depression inventory, 
(mean ± sD)
15.0 ± 13.1 20.8 ± 12.9 0.04
hamilton Anxiety rating 
scale, (mean ± sD)
13.8 ± 11.1 17.1 ± 10.7 0.22
Liebowitz social Anxiety 
scale – anxiety, (mean ± sD)
28.5 ± 19.9 28.1 ± 17.2 0.93
Liebowitz social Anxiety 
scale – avoidance,  
(mean ± sD)
27.6 ± 19.6 23.4 ± 16.5 0.42
Yale–Brown Obsessive 
compulsive scale,  
(mean ± sD)
3.3 ± 7.3 0.4 ± 2.2 0.02
Abbreviation: sD, standard deviation.
Miller et al who did not find any significant difference in the 
prevalence and the severity of depressive symptoms among 
patients with Parkinson’s disease, dystonia (focal, segmental, 
and generalized dystonia), and essential tremor.20 These 
conflicting results can be partly explained by differences 
in methods. In the study by Miller et al, the groups differed 
in age, gender, and symptom duration. In addition, these 
authors used the BDI rather than a structured clinical 
interview for psychiatric diagnosis of depression. By contrast, 
Lauterbach et al observed that atypical depression was more 
frequent in Parkinson’s disease than in dystonia.21 However, 
a recruitment bias might have interfered with their results, 
because patients with dystonia were attending a support 
group.22 It is worth mentioning that although 46.7% of our 
Parkinson’s disease patients were taking antidepressant 
drugs, this fact did not prevent us from finding increased rates 
of major depression in this group. Therefore, it is possible that 
the increased frequency of major depression in Parkinson’s 
disease may be related to the fact that Parkinson’s disease 
is a neurodegenerative disease marked by the loss of 
monoaminergic neurons. This severe neurobiological change 
may make Parkinson’s disease resistant to pharmacological 
treatment with antidepressants. Besides, the proinflammatory 
state found in Parkinson’s disease patients could make these 
patients more vulnerable to depression.22–24 In focal dystonia, 
an inflammatory state has not been described, and the changes 
observed in the brains of dystonic patients are uncovered 
only by functional neuroimaging.25 Moreover, botulinum 
toxin may display antidepressant properties.26 Given that 
focal dystonia patients were treated with botulinum toxin at 
least once, this could have influenced the frequency of major 
depression in our focal dystonia sample.
For a long time, focal dystonia had been considered a 
disorder triggered by a psychological condition, due to the 
bizarre nature of its symptoms, the variation of its intensity, 
and the sensorial tricks to disguise the movements.4 Nowadays, 
a genetic basis for the disease and the involvement of brain 
structures are recognized.4,27 Interestingly, the neurobiological 
basis proposed for focal dystonia by some authors is the 
same underlying obsessive compulsive disorder.28 Indeed, 
the presence of obsessive and avoidant personality features 
has been found in focal dystonia,29 while the presence of 
such personality traits in Parkinson’s disease remains open to 
debate.1 In our study, the prevalence of obsessive compulsive 
disorder was not significantly different between the groups, and 
the differences in YBOCS scores in favor of focal dystonia are 
within the limits of subclinical obsessive compulsive disorder. 
Although a higher frequency of obsessive compulsive disorder 
and obsessive compulsive symptoms has also been found by 
some authors,28,30,31 this is still controversial.21,32–34
The frequency of other psychiatric disorders did not differ 
between the groups. Social phobia disorder compromised 
half the patients with focal dystonia and 43% of the patients 
with Parkinson’s disease, according to the MINI-Plus. 
Accordingly, focal dystonia and Parkinson’s disease 
patients scored high in LS components, namely anxiety and 
avoidance. Previous studies have also observed an increased 
frequency of social anxiety disorder in both focal dystonia35 
and Parkinson’s disease.36 Nevertheless, in a study conducted 
by Lauterbach et al, social phobia and generalized anxiety 
disorder were more frequent in patients with dystonia, while Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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panic disorder and simple phobia were more prevalent 
in Parkinson’s disease.37 Again, important differences 
in methods may explain these contrasting results. In the 
study from Lauterbach et al, a quarter of the patients had 
generalized dystonia, and apparently none of them had ever 
used botulinum toxin.21,37 Also, dystonia group was younger 
and had more females. In addition, these authors used a 
structured interview based on DSM-III (Diagnostic and 
Statistical Manual of Mental Disorders, 3rd Edition) criteria. 
Finally, both groups were recruited from tertiary centers and 
included a small number of subjects (n = 28). Interestingly, 
they observed that generalized anxiety disorder and social 
phobia tended to develop before dystonia onset, which is in 
favor of a biological basis of these psychiatric disorders in 
this context. A common inherited genetic basis might have 
a role in some movement disorders, and their comorbid 
psychiatric disorders, through epigenetic mechanisms.38,39 
Dysfunction in frontostriatal circuitry, which responds to the 
motor symptoms and alters affective processes through limbic 
circuitry, may provide a neurobiological explanation for the 
high prevalence of social phobia in patients suffering from 
focal dystonia and Parkinson’s disease.40 Parkinson’s disease 
and focal dystonia also present some clinical features which 
are esthetically compromising and rather dysfunctional.
Considering the existence of these patients in a society 
where appearance is essential to achieve personal and 
professional success, social withdrawal and anxiety about 
social interaction are perhaps understandable.41 In animal 
studies, social phobic behavior can emerge in extremely 
aversive environments, supporting this hypothesis.42
Our study has some clear limitations. Our sample was 
recruited from a movement disorders clinic, and thus may not 
be representative of the general population. The sample size 
might also be responsible for the lack of significant differences 
regarding some psychiatric disorders, such as panic disorder, 
obsessive compulsive disorder, psychosis, and substance 
abuse. Both groups also differed in the use of psychotropic 
drugs. One additional factor restricting the generalization of 
our findings was the somewhat atypical profile of patients with 
Parkinson’s disease (ie, lower mean age and increased numbers 
of females) which were selected for the sake of comparison 
with the focal dystonia group. The lack of scales assessing 
the severity and impact of focal dystonia is another limitation. 
In Parkinson’s disease, the manifestation of depressive and 
anxious symptoms varied according to the severity and the 
stages of the disease. Because the severity of focal dystonia 
was not assessed, it was not possible to evaluate the effect of the 
severity of disease on psychiatric comorbidity when comparing 
focal dystonia and Parkinson’s disease. Other relevant missing 
information was the age at onset of the psychiatric disorder. 
Unfortunately, most patients could not remember the onset of 
their psychiatric symptoms, possibly due to the long duration 
of the disease and their limited educational level. Of note, the 
low educational level is explained by the fact that Brazil is a 
developing country, and a significant proportion of the elderly 
people could not attend school.
It would be interesting to assess pain in these patient 
groups. Because the prevalence of pain seems to be different 
in these diseases, this could have influenced the observed fre-
quency of some psychiatric disorders. Finally, the explanatory 
models of both disorders still have some problematic points. 
For instance, it is known that patients with Parkinson’s disease 
can also suffer from dystonia, which is a clinical determinant 
of health-related quality of life in these patients.43 The equal 
proportion of males and females and the similarities in other 
demographic variables, controlling for gender- and age-related 
differences in the prevalence of psychiatric disorders, may be 
considered strengths of the present study.
Conclusion
In conclusion, our study reinforces the clinical observation 
that movement disorders with different neurobiological bases 
may differ in respect of psychological and/or psychiatric pro-
file. Moreover, because there is still a gap in the literature, the 
investigation of psychiatric disorders in focal dystonia may indi-
cate the brain area involved in its pathophysiology. This study 
also suggests that physicians must be aware that the frequency 
of psychiatric disorders, such as depression and anxiety, is high 
in both diseases. Physicians who assist Parkinson’s disease and 
focal dystonia patients must diagnose and treat such symptoms 
in order to provide a better quality of life for the patients.
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